Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT04246372 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT04246372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
October 21, 2020
Completion date
October 30, 2024
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata, atopic dermatitis / eczema, down syndrome, hidradenitis suppurativa, psoriasis, vitiligo